UPDATE: BMO Capital Markets Raises PT on AbbVie on Increased Synthroid Forecasts

In a report published Friday, BMO Capital Markets analyst Alex Arfaei reiterated a Market Perform rating on AbbVie (NYSE: ABBV ), and slightly raised the price target from $42.00 to $43.00. In the report, Arfaei noted, “We are increasing our Synthroid forecasts following news that Pfizer (PFE) has voluntarily recalled